Autoimmune Response [patf]    
BRCA2 [gngm]    
CANCER [neop]    
Purpose [ftcn]    
PARP1 [gngm]    
BRCA2 [gngm]    
Synthetic [acty]    
Lethal [fndg]    
Interaction [ftcn]    
CANCER [neop]    
Methods [inpr]    
Enzyme-Linked Immunosorbent Assay [lbpr]    
detect [fndg]    
PARP1 [gngm]    
BRCA2 [gngm]    
Serum sample [bdsu]    
Including [ftcn]    
-- Breast Cancer [neop]    
Lung Cancer [neop]    
ovarian cancer [neop]    
Prostate Cancer [neop]    
Liver Cancer [neop]    
PANCREATIC CANCER [neop]    
NORMAL [qlco]    
Sera [bdsu]    
Enzyme-Linked Immunosorbent Assay [lbpr]    
confirmed [qlco]    
Immunohistochemistry [diap]    
PARP1 [gngm]    
BRCA2 [gngm]    
-- Breast Cancer [neop]    
Frequency [qnco]    
PARP1 [gngm]    
BRCA2 [gngm]    
CANCER [neop]    
Sera [bdsu]    
Cancer Patient [podg]    
tested [inpr]    
PARP1 [gngm]    
BRCA2 [gngm]    
AUTOANTIBODY RESPONSE [lbpr]    
Slightly [qlco]    
Decreased [qnco]    
Reaction [ftcn]    
Significantly high [qnco]    
AUTOANTIBODY RESPONSE [lbpr]    
PARP1 [gngm]    
BRCA2 [gngm]    
PARP1 [gngm]    
ovarian cancer [neop]    
-- Breast Cancer [neop]    
Compared [acty]    
normal control [qlco]    
Sera [bdsu]    
Immunohistochemistry [diap]    
Indicated [fndg]    
Pathology [bmod]    
Grade [clas]    
DIAGNOSIS [fndg]    
PARP1 [gngm]    
-- Breast Cancer [neop]    
Conclusions [idcn]    
Cancers [neop]    
Profile [lbpr]    
Involving [ftcn]    
Synthetic [acty]    
Lethal [fndg]    
Interaction [ftcn]    
Novel [qlco]    
Serological [ftcn]    
Biomarker [clna]    
selection [genf]    
Cancers [neop]    
